Supriya Lifescience peers

·Pharma & HealthChart ›

Companies like Supriya Lifesciencelatest year

Supriya LifescienceSUPRIYA · FY25 · this company
Market cap—
P/E—
Sales growth—
ROE—
Strides Pharma ScienceSTAR · FY26
Open ›
Market cap₹10,116
P/E18.19×
Sales growth+17.1%
ROE19.7%
Sun Pharma Advanced Research CompanySPARC · FY26
Open ›
Market cap₹5,938
P/E3.82×
Sales growth+314.1%
ROE277.4%
Thyrocare TechnologiesTHYROCARE · FY26
Open ›
Market cap₹8,205
P/E50.19×
Sales growth+25.1%
ROE28.8%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUPRIYA₹869.30

Supriya Lifescience Ltd.

· Pharma & Health
₹ CrorePeersSTARSPARCTHYROCARESHILPAMEDVIYASHRUBICONYATHARTHPARKHOSPS
Comp Set
In ₹ Crore except Per Share
Latest Annual
SUPRIYA
FY25
STAR
FY26
SPARC
FY26
THYROCARE
FY26
Peer
Average
Valuation — at last close
P/E—18.19×◆ 3.82×50.19×24.07×
P/B—◆ 3.26×4.43×14.02×7.24×
EV/EBITDA—12.55×◆ 4.06×30.48×15.70×
Market Cap—₹10,116 Cr₹5,938 Cr₹8,205 Cr₹8,086 Cr
Growth
Revenue CAGR 3Y—9.62%◆ 95.98%16.33%40.64%
Revenue CAGR 5Y—7.94%—◆ 10.88%9.41%
Net Income CAGR 3Y———36.27%36.27%
Revenue YoY (latest Q)—17.11%◆ 314.11%25.07%118.76%
Net Income YoY (latest Q)—1.97%◆ 59.94%-68.17%-2.09%
Profitability
EBITDA Margin—19.04%◆ 85.08%31.61%45.24%
Net Income Margin—11.82%◆ 82.65%19.64%38.04%
Return on Common Equity—19.66%◆ 277.35%28.80%108.60%
Return on Capital Employed—19.31%◆ 230.55%33.68%94.51%
Return on Assets—8.86%◆ 123.94%22.62%51.81%
Credit & Quality
Total Debt/Equity◆ 0.00×0.53×0.42×0.00×0.32× -100%
Interest Coverage—4.05×46.54×◆ 72.66×41.08×
Scale — latest FY
Revenue / Total Income—₹4,859 Cr₹1,879 Cr₹829 Cr₹2,522 Cr
Net Income—₹575 Cr₹1,553 Cr₹163 Cr₹764 Cr
Total Assets₹1,112 Cr₹6,927 Cr₹2,171 Cr₹747 Cr₹3,282 Cr -66%
EPS—₹60.34₹47.86₹10.27₹39.49
Book Value per Share—₹337.14₹41.26₹36.78₹138.39
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 89%.